TGFB1 and breast carcinoma: BML284-treated macrophage-derived CM also downregulated Lrp5, Runx2, and TGFβ, and it reduced the size of human breast-cancer-tissue fragments (ER-/PR+/HER2+) ex vivo in 3 days (Figure 7D).